Ongoing Study:

Phase 1a Study in COVID-19 in the United Kingdom

First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Overlapping Single and Multiple Ascending Dose Escalation Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers

Study Highlights:

Enrolling: ~80 Subjects

Treatment period: Single ascending dose (SAD) and multiple ascending dosing (MAD)

Primary Endpoint: Safety and tolerability

For complete study details, please view the study listing on Identifier: NCT05195723

Our Pipeline


Sign Up For Alerts